Obstetrics and Gynecology

David P. Bender, MD


Clinical Associate Professor
Clinical Associate Professor of Obstetrics and Gynecology  - Gynecologic Oncology

Contact Information

Primary Office: 31507 PFP
200 Hawkins Dr
Iowa City, IA 52242
Phone: 319-356-2015

Email: david-bender@uiowa.edu


BA, Bowdoin College, Brunswick, Maine
MD, Medicine, Finch University of the Health Sciences/The Chicago Medical School, North Chicago, Illinois

Residency, Obstetrics and Gynecology & Reproductive Sciences, Magee-Women's Hospital, University Health Center of Pittsburgh, Pittsburgh, Pennsylvania
Fellowship, Department of OB/GYN, University of Louisville School of Medicine
Fellowship, Gynecologic Surgery, University of Iowa Hospitals and Clinics
Fellowship, Gynecologic Oncology, University of Iowa Hospitals and Clinics

Licensure and Certifications

Subspecialty Certification in Gynecologic Oncology
Board Certification in Obstetrics & Gynecology
Iowa Medical License #33545

All Publications

Christensen D, Armaiz-Pena G, Ramirez E, Matsuo K, Zimmerman B, Zand B, Shinn E, Goodheart M, Bender D, Thacker P, Ahmed A, Penedo F, DeGeest K, Mendez L, Domann F, Sood A, Lutgendorf S.  SSRI use and clinical outcomes in epithelial ovarian cancer .  Oncotarget .  2016 April 21. 7(22):33179-91.

Davis L, Slavich G, Thacker P, Goodheart M, Bender D, Dahmoush L, Farley D, Markon K, Penedo F, Lubaroff D, Cole S, Sood A, Lutgendorf S.  Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer.  Cancer .  2015 October 1. 121(19):3543-50.

Bender D, Sill M, Lankes H, Reyes H, Darus C, Delmore J, Rotmensch J, Gray H, Mannel R, Schilder J, Hunter M, McCourt C, Samuelson M, Leslie K.  A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study .  Gynecol Oncol.  2015 September. 138(3):507-12.

Stephan J, Goodheart M, McDonald M, Hansen J, Reyes H, Button A, Bender D.  Robotic surgery in super-morbidly obese patients with endometrial cancer.  Am J Obstet Gynecol .  2015 July. 213(1):49.e1-8.

Hansen J, Stephan J, Freesmeier M, Bender D, Button A, Goodheart M.  The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients .  Gyncol Oncol.  2015 July. 138(1):154-8.

Coleman R, Sill M, Thaker P, Bender D, Street D, McGuire W, Johnston C, Rotmensch J.  A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.  Gynecol Oncol.  2015 April 14. pii: S0090-8258(15):00795-7.

Kunos C, Deng W, Dawson D, Lea J, Zanotti K, Gray H, Bender D, Guaglianone P, Carter J, Moore K.  A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study.  Int J Gynecol Cancer .  2015 March. 25(3):484-92.

Schrepf A, Thaker P, Goodheart M, Bender D, Slavich G, Dahmoush L, Penedo F, DeGeest K, Mendez L, Labaroff D, Cole S, Sood A, Lugendorf S.  Diurnal cortisol and survival in epithelial ovarian cancer.  Psychoneuroendocrinology.  2015 March. 53:256-67.

Alvarez R, Sill M, Davidson S, Muller C, Bender D, Debernardo R, Behbakht K, Huh W.  A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study..  Gynecol Oncol.  2014 June. 133(3):433-8.

Stephan J, Hansen J, Samuelson M, McDonald M, Chin Y, Bender D, Reyes H, Button A, Goodheart M.  Intra-operative frozen section results reliably predict final pathology in endometrial cancer..  Gynecol Oncol. .  2014 April 1. 

Lutgendof S, Slavich G, Degeest K, Goodheart M, Bender D, Thaker P, Penedo F, Zimmerman B, Lucci III J, Mendez L, Collins K, Sood A.  Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients.  Gynecol Oncol.  2013 December. 131(3):667-73.

Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, Dahmoush L, Penedo F, Lucci III J, Thaker P, Mendez L, Sood A, Slavich G, Lutgendof S.  Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis.  Cancer.  2013 September 1. 119(17):3234-41.

Nadkarni N, Geest K, Neff T, Young B, Bender D, Ahmed A, Smith B, Button A, Goodheart M.  Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer..  Cancer letters.  2013 April. 331(1):99-104.

Schrepf A, Clevenger L, Christensen D, De Geest K, Bender D, Ahmed A, Goodheart M, Dahmoush L, Penedo F, Lucci III J, Ganjei-Azar P, Mendez L, Markon K, Lubaroff D, Thaker P, Slavich G, Sood A, Lutgendorf S.  Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: Relationships with depression, fatigue, and disability.  Brain Behav Immun.  2013 March 15. 30, Supplement:S126-S134.

Clevenger L, Schrepf A, Christensen D, De Geest K, Bender D, Ahmed A, Goodheart M, Penedo F, Lubaroff D, Sood A, Lutgendorf S.  Sleep disturbance, cytokines, and fatigue in women with ovarian cancer..  Brain, Behavior, and Immunity.  2012 October. 26(7):1037-44.

Engle D, Connor J, Morris P, Bender D, De Geest K, Ahmed A, Goodheart M.  Intraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial..  Archives of gynecology and obstetrics.  2012 September. 286(3):717-21.

Lutgendorf S, De Geest K, Bender D, Ahmed A, Goodheart M, Dahmoush L, Zimmerman M, Penedo F, Lucci III J, Genjei-Azar P, Thaker P, Mendez L, Lubaroff D, Slavich G, Cole S, Sood A.  Social Influences on Clinical Outcomes of Patients with Ovarian Cancer.  Journal of Clinical Oncology.  2012 August 10. 30(23):2885-90.

Shelton D, Fornalik H, Neff T, Park S, Bender D, De Geest K, Liu X, Xie W, Meyerholz D, Engelhardt J, Goodheart M.  The Role of LEF1 in Endometrial Gland Formation and Carcinogenesis.  PLoS One.  2012 July 6. 7(7):e40312.

Shamshirsaz A, Buekers T, De Geest K, Bender D, Zamba G, Goodheart M.  A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival.  International Journal of Gynecological Cancer .  2011 October. 21(7):1232-40.

Lutgendorf S, De Geest K, Dahmoush L, Farley D, Penedo F, Bender D, Goodheart M, Buekers T, Mendez L, Krueger G, Clevenger L, Lubaroff D, Sood A, Cole S.  Social Isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients.  Brain Behav Immun.  2011 February. 25(2):250-5.

Lutgendorf S, Mullen-Houser E, Russell D, De Geest K, Jacobson G, Hart L, Bender D, Anderson B, Buekers T, Goodheart M, Antoni M, Sood A, Lubaroff D.  Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach.  Brain, Behavior and Immunity.  2010 November. 24(8):1231-40.

Weinrib A, Sephton S, De Geest K, Penedo F, Bender D, Zimmerman B, Kirschbaum C, Sood A, Lubaroff D, Lutgendorf S.  Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer.  Cancer.  2010 September 15. 116(18):4410-9.

Modesitt S, Sill M, Hoffman J, Bender D.  A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study..  Gynecologic oncology.  2008 May. 109(2):182-6.

Covens A, Blessing J, Bender D, Mannel R, Morgan M.  A Phase II Evaluation of Tirapazamine plus Cisplatin in the Treatment of Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study.  Gynecologic Oncology.  2006 March. 100(3):586-590.

Han L, Landen C, Kamat A, Lopez A, Bender D, Mueller P, Schmandt R, Gershenson D, Sood A.  Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  2006 February. 24(5):755-61.

Sharma N, Sorosky J, Bender D, Fletcher M, Sood A.  Malignant Mixed Mullerian Tumor (MMMT) of the Cervix.  Gynecologic Oncology.  2005 March. 97:442-445.

Bender D, Sorosky J, Buller R, Sood A.  Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma..  American journal of obstetrics and gynecology.  2003 July. 189(1):113-7.

Bender D, Cooper B, Sorosky J, Sood A.  Placental growth factor (PlGF) is a novel prognostic marker in ovarian cancer.  2003 January. 

Bender D, Mahavni V, Kim S, Zogg M, Ritchie J, Buller R.  Novel sites and markers enhance the detection of x-inactivation in ovarian cancer.  2002 June. 

Bender D, Sood A, Sorosky J, Anderson B, Buller R.  The prognostic value of a pretreatment serum CA-125 in cervical adenocarcinoma.  2002 March. 

Lowe M, Bender D, Sood A, Davis W, Syrop C, Sorosky J.  Delivery of Twin Gestations Following Conservative Treatment of Endometrial Cancer and Assisted Reproduction.  Fertility and Sterility.  2002. 77:188-189.

Taylor D, Bender D, Gerçel-Taylor C, Stanson J, Whiteside T.  Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients..  British journal of cancer.  2001 June. 84(12):1624-9.

Bender D, Sood A, Sorosky J, Anderson B, Butler R.  The value of pretreatment serum CA-125 in cervical adenocarcinoma.  2001 June. 

Bender D, Sood A.  Chemoradiation for the Treatment of Cervical Cancer: A New Paradigm.  Postgraduate Obstetrics and Gynecology.  2001. 21:1-6.

Friebe-Hoffmann U, Bender D, Sims C, Rauk P.  Candida albicans chorioamnionitis associated with preterm labor and sudden intrauterine demise of one twin. A case report..  The Journal of reproductive medicine.  2000 April. 45(4):354-6.

Bender D, Makhija S, Taylor D, Gercel-Taylor C.  Cisplatin and taxol-induced caspase-3 activity in ovarian cancer cell monolayer and spheroids.  2000 April. 

Bender D, Sullivan S, Gercel-Taylor C, Taylor D.  Modulation of T-cell receptor zeta chain expression in pregnancy.  2000 March. 

Bender D, Gercel-Taylor C, Taylor D.  Isolation of a soluble inhibitor of zeta chain expression in gynecologic malignancies.  2000 February. 

Resnik E, Bender D.  Syndrome of Inappropriate Antidiuretic Hormone Secretion in Papillary Serous Surface Carcinoma of the Peritoneum.  Journal of Surgical Oncology.  1996 January. 61:63-65.

Clodfelter S, Doede T, Brennan B, Nagle J, Bender D, Turner W, Lapunzina P.  Luminescent Metal-Metal Bonded Exciplexes Involving Tetrakis (mu-diphosphito) diplatinate (II) and Thallium (I).  Journal of the American Chemical Society.  1994 December 1. 116.

Bender D, Nagle J.  Metal-Metal Interactions of Aqueous Lead (II) and Tin (II) Ions with the Ground and Excited States of Tetrakis (mu-diphosphito) diplatinate (II).  Inorganica Chimica Acta.  1994 October 1. 225:201-205.

Date Last Modified: 06/06/2016 - 13:17:48